题名 |
乳癌患者服用人參之安全性探討 |
并列篇名 |
Safety Issues for Those Patients with Breast Cancer who Take Ginseng |
DOI |
10.6718/TJCM.201909_25(2).0004 |
作者 |
陳安履(An-Lu Chen);林舜穀(Shun-Ku Lin) |
关键词 |
乳癌 ; 人參 ; 子宮內膜癌 ; 人參皂苷 ; 中西藥交互作用 ; Breast cancer ; Ginseng ; endometrial carcinoma ; Ginsenoside ; Herbal-drug Interactions |
期刊名称 |
台北市中醫醫學雜誌 |
卷期/出版年月 |
25卷2期(2019 / 09 / 30) |
页次 |
23 - 30 |
内容语文 |
繁體中文 |
中文摘要 |
許多乳癌患者會接受中醫治療,也會服用包含人身的中藥方劑。但許多患者與臨床醫師擔心人參可能會加速乳癌細胞分裂,建議患者避免服用。細胞試驗表明人參會刺激乳癌細胞的雌激素受體,增加DNA和RNA的表現,但反而會降低癌細胞的存活率。此外,大規模的病人數據追蹤結果顯示,正在接受Tamoxifen治療的乳癌患者,若也接受人參治療並不會增加子宮內膜癌的風險。而更年期婦女服用人參,也不會增加罹患乳癌的風險。 |
英文摘要 |
Many patients with breast cancer pursue Traditional Chinese medication (e.g., Chinese medicine compounds containing Ginseng). However, some clinical doctors recommend patients to avoid taking Ginseng since it may enhance cytokinesis of cancer cells. In fact, cell tests revealed that Ginseng can enhance the activity of estrogen receptor of breast cancer cells. As a result, the survival rate of cancer cells is greatly reduced. Furthermore, the data base established by retrospective studies showed that Ginseng did not increase the risk of endometrial carcinoma for those patients with breast cancer who took Tamoxifen. In addition, Ginseng does not cause the increased risk of breast cancer in menopausal women. |
主题分类 |
醫藥衛生 >
中醫藥學 |
参考文献 |
|
被引用次数 |